REGISTER
Dr. David Planchard at WCLC 2025
Recent data bring fresh attention to Dr. David Planchard at WCLC 2025. The article traces the core results involving WCLC, MD, OS and explains their implications for routine care and future research.

MedJ Takes You to WCLC 2025

David Planchard, MD, Gustave Roussy Cancer Center, France. In-Depth Analysis of FLAURA2 Final OS Results, Revealing How Osimertinib Combined with Chemotherapy Reshapes the First-Line Treatment Landscape for EGFR-Mutated Lung Cancer!

0
0
Loading